

1 **Circulatory dietary and gut-derived metabolites predict preclinical Alzheimer's disease.**

2 Emily Connell¹, Saber Sami¹, Mizanur Khondoker¹, Anne-Marie Minihane¹, Matthew G. Pontifex¹,

3 Michael Müller¹, Simon McArthur², Gwenaelle Le Gall^{1†} and David Vauzour^{1†*}

4 ¹ Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia,

5 Norwich NR4 7TJ, United Kingdom.

6 ² Institute of Dentistry, Faculty of Medicine & Dentistry, Queen Mary University of London, Blizard

7 Institute, London E1 2AT, United Kingdom

8

9 † These authors share senior authorship

10 * To whom correspondence should be addressed: Dr David Vauzour; email: D.Vauzour@uea.ac.uk

11 **Abstract**

12 A key component of disease prevention is the identification of at-risk individuals. Microbial dysbiosis
13 and microbe-derived metabolites (MDM) can influence the central nervous system, but their role in
14 disease progression and as prognostic indicators is unknown. To identify preclinical factors associated
15 with Alzheimer's disease (AD), we compared gut microbiome and metabolome profiles of cognitively
16 healthy subjects, subjective cognitive impairment (SCI) participants and mild cognitive impairment
17 (MCI) participants (n=50 per group, matched for age, BMI and sex), targeting metabolites previously
18 associated with cognitive health (TMAO, bile acids, tryptophan, *p*-cresol and their derivatives). 16S
19 rRNA bacterial microbiome sequencing and targeted LC-MS/MS were employed for faecal
20 microbiome speciation and serum MDM quantification. Microbiome beta diversity differed between
21 healthy controls and SCI participants. Multiple linear regression modelling highlighted five serum
22 metabolites (indoxyl sulfate, choline, 5-hydroxyindole acetic acid, indole-3-propionic acid (IPA) and
23 kynurenic acid) significantly altered in preclinical AD. Neuroprotective metabolites, including
24 choline, 5-hydroxyindole acetic acid and IPA, exhibited lower concentrations in SCI and MCI in
25 comparison to controls, while the cytotoxic metabolite indoxyl sulfate had higher levels. A Random
26 Forest algorithm with multiclass classification confirmed and extended our results, identifying six
27 metabolites (indoxyl sulfate, choline, 5-hydroxyindole acetic acid, IPA, kynurenic acid, kynurenine)
28 as predictors of early cognitive decline, with an area under the curve of 0.74. In summary, a combined
29 statistical and machine learning approach identified MDM as a novel composite risk factor for the
30 early identification of future dementia risk.

31

32 **Keywords:** microbiome, indoxyl sulfate, indole-3-propionic acid, 5-hydroxyindole acetic acid,
33 choline, kynurenic acid, mild cognitive impairment, subjective cognitive impairment.

34 1. Introduction

35 Currently, an estimated 55.2 million people suffer from dementia worldwide, of which Alzheimer's
36 disease (AD) is the main form¹. In the absence of an effective strategy to slow or prevent disease
37 progression, dementia incidence is expected to increase to 152.8 million by 2050. By the time AD is
38 typically diagnosed, substantial neuronal loss will have occurred across multiple brain regions.
39 Identifying molecular precursors and biological risk factors at preclinical disease stages would enable
40 earlier detection and the targeting of regular monitoring and mitigating interventions while prevention
41 is viable.

42 The contribution of lifestyle factors to cognitive decline and dementia is well documented^{2,3}. Diet in
43 particular has emerged as a key influencer of brain health and AD development, in part by modulating
44 communication along the microbiota-gut-brain axis. This axis forms a bidirectional communication
45 system comprising neuronal, endocrine, immune and metabolic signalling mechanisms linking the gut
46 and the central nervous system (CNS)⁴. Gut microbes regulate this communication via the breakdown
47 of dietary compounds into bioactive metabolites. Such microbe-derived metabolites (MDM)
48 subsequently modulate pathways affecting the CNS both directly, by crossing the blood-brain barrier
49 and indirectly, via modulation of peripheral organ function or vagus nerve stimulation⁵. In the
50 prodromal stages of AD, for example mild cognitive impairment (MCI), the microbiota-gut-brain axis
51 becomes dysregulated (i.e., dysbiosis), a change associated with pathological processes such as
52 neuroinflammation and neural injury, and thought to contribute to accelerating cognitive decline⁶⁻⁸.
53 However, the mechanism(s) underlying these changes, and the role of MDM in this process remains
54 unknown.

55 Several examples of MDM have been linked to cognitive health⁵, including trimethylamine N-oxide
56 (TMAO)⁹⁻¹², bile acids (BAs)¹³⁻¹⁵, tryptophan¹⁶⁻¹⁹, *p*-cresol and its derivatives^{20,21}. Notably, these
57 same MDM have been further linked to pathological processes known to be associated with AD²¹⁻²⁸,
58 including neuroinflammation, synaptic damage and blood-brain barrier disruption, but whether
59 changes in these MDM are drivers or correlates of disease processes requires comprehensive
60 investigation.

61 Targeted metabolomics presents a powerful tool to comprehensively assess changes in the
62 endogenous metabolome. Here, we present a targeted metabolomics approach employing liquid
63 chromatography-tandem mass spectrometry (LC-MS/MS) to quantify TMAO, BAs, tryptophan and *p*-
64 cresol metabolite profiles in the serum of healthy controls and participants in early cognitive decline.
65 Early cognitive decline comprises individuals with subjective cognitive impairment (SCI) and mild
66 cognitive impairment (MCI), the preclinical stages of AD progression. This study presents, for the
67 first time, the prognostic value of key metabolites in combination and represents one of only a few

68 studies characterising metabolic perturbations in the early stages of cognitive decline, including
69 participants undergoing the earliest preclinical stage of AD, SCI.

70 **2. Materials and methods**

71 2.1 Study samples

72 Human serum samples from the baseline measurements of two previously conducted clinical studies
73 were used: (1) the impact of Cranberries On the Microbiome and Brain in healthy Ageing sTudy
74 (COMBAT; NCT03679533) and (2) the Cognitive Ageing, Nutrition and Neurogenesis (CANN;
75 NCT02525198) study. The COMBAT study recruited 60 adults, aged 50-80 years, with no subjective
76 memory complaints as assessed by the Cognitive Change Index (CCI) questionnaire ²⁹. The CANN
77 study recruited 259 participants, aged ≥ 50 years, with subjective cognitive impairment (SCI) or mild
78 cognitive impairment (MCI) based on criteria developed by the National Institute of Aging-
79 Alzheimers Association, with no indication of clinical dementia ³⁰. Cognitively healthy adults were
80 selected from the COMBAT study as a control group, with all groups (controls, SCI and MCI, n=50
81 per group) matched for age, BMI and sex as these are key variables known to affect microbiome
82 composition ^{31,32}. Participants with chronic fatigue syndrome, liver disease, diabetes mellitus, or gall
83 bladder abnormalities were excluded.

84 Cognitive health was assessed using a variety of cognitive tests in both the COMBAT and CANN
85 study. However, only the Trail Making Test (assessing visual processing speed, scanning, mental
86 flexibility, as well as executive function) and the digit span test (assessing verbal short-term and
87 working memory) were used across the COMBAT and CANN studies enabling comparisons.
88 Participants also completed a validated, semi-quantitative Scottish Collaborative Group (SCG) food
89 frequency questionnaire (version 6.6) to assess background diet ³³. Biochemical analyses of blood
90 glucose, liver function (bilirubin, albumin, aspartate aminotransferase (AST), alanine
91 aminotransferase (ALT) and AST/ALT ratio), kidney function (creatinine) and serum lipid
92 concentrations (total-, LDL-, HDL-cholesterol and triglyceride) were conducted in all participants.
93 The protocols were approved by the UK National Research Ethics Service (NRES) Committee, (Study
94 ID: 14/EE/0189) for CANN and by the University of East Anglia's Faculty of Medicine and Health
95 Sciences Ethical Review Committee (Reference: 201819-039) and the UK Health Research Authority
96 (IRAS number: 237251) for COMBAT. The participants provided written informed consent to
97 participate.

98

99 2.2 Microbiome Profiling

100 Microbiome analysis was performed by 16S rRNA sequencing as previously reported³⁴. In brief,
101 DNA extraction was performed from approximately 50 mg of faecal content using the QIAamp
102 PowerFecal Pro DNA Kit (Qiagen, Manchester, UK) as per the manufacturer's instructions. DNA
103 quantity was evaluated using a Nanodrop 2000 Spectrophotometer (Fisher Scientific, UK). Quality
104 assessment by agarose gel electrophoresis distinguished the DNA integrity, purity, fragment size and
105 concentration. Illumina NovaSeq 6000 PE250 was used to amplify the V3–V4 hypervariable region.
106 Sequence analysis was carried out using Uparse software (Uparse v7.0.1001)³⁵, incorporating all the
107 effective tags. Sequences sharing a similarity of $\geq 97\%$ were grouped into the same Operational
108 Taxonomic Unit (OTU). A representative sequence for each OTU was screened for further annotation.
109 A representative OTU sequence was further analysed using the SSUrRNA database of SILVA
110 Database 138³⁶. OTU abundance data were normalised using a standard sequence number
111 corresponding to the sample with the least sequences. Alpha diversity was assessed using both Chao1
112 and Shannon H diversity indices, whilst beta diversity was assessed using Bray–Curtis dissimilarity.
113 Statistical significance was determined by Kruskal–Wallis or Permutational Multivariate Analysis of
114 Variance (PERMANOVA). Comparisons at the phylum and genus level were made using classical
115 univariate analysis using Kruskal–Wallis combined with a false discovery rate (FDR) approach used
116 to correct for multiple testing. P-values below 0.05 were considered statistically significant.

117

118 2.3 Metabolite Profiling

119 Serum samples were diluted with methanol at a ratio of 1:10 (v/v) and placed on dry ice for 10 min.
120 Samples were then centrifuged (5 min, 16,000x g at room temp), supernatants filtered using a 0.45
121 μM PTFE syringe filter and evaporated to dryness using a SavantTM SpeedVacTM High-Capacity
122 Concentrator (ThermoFisher, UK). Dried samples were resuspended in either 50 μL of methanol with
123 the addition of 15 μL of lithocholic acid-d4 and cholic acid-d4 at 50 $\mu\text{g}/\text{mL}$ for the detection of bile
124 acids, 50 μL water with TMA-d9 N-oxide, TMA 13C 15N hydrochloride at 50 $\mu\text{g}/\text{mL}$ for the
125 detection of TMAO/TMA/choline or 50 μL water with 15 μL of L-methionine-3, 3, 4, 4 d4 and p-
126 toluenesulfonic acid at 50 $\mu\text{g}/\text{mL}$ for the detection of tryptophan and *p*-cresol metabolites
127 respectively. All internal standards were supplied by ThermoFisher, UK. Samples were analysed using
128 the Waters Acquity UPLC system and Xevo TQ-S Cronos mass spectrometer with MassLynx 4.1
129 software. See supplementary methods for full details.

130

131 2.4 Statistical Analyses

132 Significant associations of metabolites with cognitive status were identified using multiple linear
133 regression analysis. Covariates known to affect metabolome or microbiome composition, including
134 age, BMI, diet and markers of kidney function (creatinine) and liver function (AST/ALT ratio), were

135 included in the model³⁷⁻⁴¹. Sex was not included as a covariate as all groups had an equal proportion
136 of males and females. Diet was assessed using a validated, semi-quantitative Scottish Collaborative
137 Group (SCG) food frequency questionnaire (version 6.6)³³. Participants' dietary components were
138 grouped (kcal, proteins, fats, carbohydrates, water, alcohol, vitamins and minerals) and analysed using
139 hierarchical clustering via Ward's linkage method to assemble individuals with similar dietary
140 patterns (Supplementary Figure S1). This clustered participants into low, moderate and high intake of
141 dietary components and was added to the model as a categorical variable, with participants with a
142 moderate intake used as a reference group. Age, BMI, creatinine and AST/ALT ratio were added to
143 the model as continuous variables. Finally, cognitive status (i.e., control, SCI and MCI) was added to
144 the model as a categorical variable. Metabolite concentrations outside ± 2 standard deviations from
145 the mean were excluded as outliers. The assumptions for multiple linear regression analysis including
146 the existence of a linear relationship among the outcome and predictor variable, normality and
147 homoscedasticity were assessed (Supplementary Figure S2). The model tested for significant
148 associations between metabolite and cognitive status, adjusting for the included covariates. All
149 multiple linear regression analyses were performed in R (v3.6.3; R Foundation: A Language and
150 Environment for Statistical Computing).

151

152 2.5 Machine Learning

153 A Random Forest (RF) machine learning algorithm was implemented to assess whether metabolites
154 could be predictive of preclinical AD. The RF model was constructed using 100 decision trees and 6
155 random variables considered at each split. The number of variables considered per split corresponds to
156 the square root of the total number of attributes in the data⁴² (as 32 variables were considered, this
157 resulted in ~6 random variables per split). To create a composite panel to predict preclinical AD,
158 metabolites were ranked according to the mean decrease Gini. This highlights the loss in model
159 performance when permuting the predictor values, and can provide more robust results than mean
160 decrease accuracy⁴³. The metabolites with the highest mean decrease Gini score producing the
161 highest AUC values were retained in the model. To compare our model, Naive Bayes and AdaBoost
162 machine learning models were also constructed^{44,45}. AdaBoost predictions were made by using a
163 weighted average of weak classifiers. Our model contained 50 estimators, a learning rate of 1.00 and a
164 SAMME classification algorithm which updated the base estimator's weights with classification
165 results. The Naive Bayes method was applied based on applying Bayes' theorem with the "naive"
166 assumption of conditional independence between every pair of features given the value of the target
167 variable. The dataset for multi-class classification was randomly divided into training and testing,
168 with 75% of the samples allocated to the training set and 25% to the testing set. Models were assessed
169 by the average area under the receiver operator curve (AUC) (plotting the false positive rate against

170 the true positive rate) over all classes (macro-average) as an indication of model performance. All
171 machine learning models were built in Python (Python Software Foundation. Python Language
172 Reference, version 3.8).

173

174 **3. Results**

175 3.1 Study population characteristics

176 A total of 150 individuals were included in the study of which 50 (33.3%) were cognitively healthy,
177 50 (33.3%) presented with SCI and 50 (33.3%) with MCI. The mean \pm SD age of all participants was
178 65.5 ± 5.7 years, with a mean level of education of 14.6 ± 3.5 years and 54% female (Table 1).
179 Cognitive groups were matched for age, BMI and sex ($p= 0.99$). Participants in both the COMBAT
180 and CANN study undertook several cognitive assessments at their baseline visit ^{29,30}. Significant
181 differences were found in the Trail Making Test B, digit span backward test and digit span total score
182 between groups ($p<0.05$). There was a marginal difference between the three groups in the Trail
183 Making Test A ($p= 0.09$) and no significant difference occurred in the digit span forwards test ($p=$
184 0.21). The prevalence of the *APO* $\epsilon 4$ was lower in controls (18%) compared to SCI (26%) and MCI
185 (38%) participants.

186 Albumin, bilirubin and fasting glucose ($p<0.01$) differed according to cognitive status. Interestingly,
187 both albumin and bilirubin were highest in controls and lowest in SCI participants. Although
188 participants diagnosed with diabetes mellitus were excluded, fasting glucose increased over
189 preclinical AD, with the lowest concentrations in control individuals and the highest in MCI (Table
190 1).

191

192 3.2 Gut microbiome and metabolome shifts in preclinical AD

193 Alpha diversity was measured using the Chao1 ($p= 0.21$) and Shannon H ($p= 0.70$) indices with no
194 significant difference amongst groups (Figure 1A-B). Conversely, beta diversity, as measured by
195 Bray-Curtis dissimilarity, was significantly different (PERMANOVA F-value= 1.35, $p= 0.02$) (Figure
196 1C). Pairwise analysis suggested the shift was primarily driven by the differences between the control
197 and SCI groups (FDR $q= 0.03$), rather than between SCI and MCI (FDR $q= 0.38$) or MCI and control
198 (FDR $q= 0.15$) (Figure 1D). The PLS-DA plot suggested similar patterns in participants' metabolomic
199 profiles, with control separating from SCI and MCI (Figure 2A). The extent of this separation can be
200 seen through the heatmap displaying shifts in metabolite concentrations between groups and
201 clustering SCI and MCI together (Figure 2B). The similarity between microbiome and metabolomic
202 profiles was confirmed by conducting a Procrustes analysis to evaluate the congruence of the two

203 datasets. The analysis revealed strong similarity between the metabolome and microbiome results in
204 control and SCI ($R= 0.21$, $p= 0.03$), SCI and MCI ($R= 0.27$, $p= 0.002$) and MCI and control ($R= 0.26$,
205 $p= 0.002$) groups (Supplementary Figure S3).

206
207 3.3 Serum metabolites significantly associated with early cognitive decline in an adjusted
208 multivariable model

209 Multiple linear regression analysis adjusted for liver function (AST/ALT ratio), kidney function
210 (creatinine), age, BMI and background diet identified five metabolites significantly associated with
211 early cognitive decline, including choline, 5-hydroxyindole acetic acid, indole-3- propionic acid
212 (IPA), indoxyl sulfate and kynurenic acid (Table 1). Indoxyl sulfate, choline and 5-hydroxyindole
213 acetic acid were associated with both SCI and MCI ($p<0.05$). Kynurenic acid was significantly
214 associated with SCI ($\beta= 0.007$, 95% CI: <0.001 , 0.014 , $p= 0.037$) but not MCI ($\beta= 0.001$, 95% CI: -
215 0.006 , 0.007 , $p= 0.874$). On the other hand, IPA was significantly associated with MCI ($\beta= -0.558$,
216 95% CI: -0.910 , -0.206 , $p= 0.002$), but not SCI ($\beta= -0.181$, 95% CI: -0.536 , 0.174 , $p= 0.316$).
217 Neuroprotective metabolites, including choline, 5-hydroxyindole acetic acid and indole propionic acid
218 ⁴⁶⁻⁴⁸, exhibited lower concentrations in SCI and MCI participants in comparison to controls, while
219 metabolites linked to cytotoxicity, including indoxyl sulfate, showed increasing levels ⁴⁹. Kynurenic
220 acid, a typically neuroprotective metabolite ⁵⁰, was higher in SCI and MCI in comparison to controls.
221 Group means for all metabolite concentrations are given in Supplementary Table S1.

222
223 3.4 Machine learning models to identify risk factors predictive of preclinical AD

224 All 32 serum metabolites were initially evaluated as possible predictors of preclinical AD. RF
225 achieved the highest classification AUC of 0.65, with AdaBoost and Naïve Bayes attaining 0.58 and
226 0.63 respectively (Supplementary Table S2). Using the mean decrease Gini, the importance of each
227 metabolite was assessed (Figure S4). Six metabolites (5-hydroxyindole acetic acid, indole-3-propionic
228 acid, choline, indoxyl sulfate, kynurenic acid and kynurenine) produced the highest AUC of 0.74
229 using the RF classification algorithm (Figure 4). In comparison, Naive Bayes achieved an AUC of
230 0.72 and AdaBoost attained 0.68. The RF ROC curve indicated the model's predictive performance
231 was highest for controls (AUC= 0.79), followed by MCI (AUC= 0.76) and SCI (AUC= 0.64). As
232 such, we investigated whether the model performance would be improved by predicting only healthy
233 ageing and MCI. Using the six serum metabolites from controls and MCI participants, the RF model
234 showed improved predictive performance (AUC= 0.84) (Supplementary Table S2). AdaBoost and
235 Naive Bayes also demonstrated increased performance, attaining AUC of 0.87 and 0.90 respectively.

236

237 3.5 Serum dietary and MDM and gut microbiome modulation in preclinical AD are significantly
238 linked

239 Having identified a shift in both the microbiome and metabolome profiles, a Spearman correlation
240 examined possible connections between the two datasets. Significantly modulated metabolites and
241 microbiome genera between the three groups ($p < 0.05$) were correlated, revealing bacterial–metabolite
242 interactions. Control and SCI participants displayed a negative relationship between 5-hydroxyindole
243 acetic acid and *Lachnoclostridium* ($R = -0.29$, $p = 0.004$), indoxyl sulfate and *Turicibacter* ($R = -0.21$,
244 $p = 0.038$), and choline and *Lachnoclostridium* ($R = -0.36$, $p = 0.0002$) and *Ruminococcus gnavus* group
245 ($R = -0.28$, $p = 0.005$) (Figure 3A). Choline and *UCG-009* ($R = 0.316$, $p = 0.002$), anthranilic acid and
246 *Lactonifactor* ($R = 0.24$, $p = 0.019$) and *Holdemanella* ($R = 0.24$, $p = 0.02$), indoxyl sulfate and
247 *Holdemania* ($R = 0.318$, $p = 0.001$) and *Lactonifactor* ($R = 0.33$, $p = 0.0008$) had a positive correlation.
248 Between SCI and MCI participants, only IPA and *Lachnospiraceae ND3007* group had a positive
249 correlation ($R = 0.26$, $p = 0.011$) (Figure 3B).

250 As indoxyl sulfate, choline, 5-hydroxyindole acetic acid and IPA were identified as risk factors of
251 cognitive decline, genera correlated with these metabolites were investigated further to identify
252 potential associations with their production. *Holdemania* and *Lachnoclostridium* genera were higher
253 in SCI participants in comparison to controls but lower in SCI relative to MCI (Figure 3C-D). On the
254 other hand, *Turicibacter* were higher in both SCI and MCI participants in comparison to controls
255 (Figure 3E). The abundance of *UCG-009* was significantly lower in both SCI and MCI participants in
256 comparison to controls (Figure 3F). *Lactonifactor* and *Ruminococcus gnavus* were both higher in SCI
257 in comparison to controls (Figure G-H). Finally, *Lachnospiraceae ND3007* was not different between
258 control and SCI but was lower in SCI compared to MCI (Figure 3I).

259 260 **4. Discussion**

261 Identification of robust, inexpensive and non-invasive markers of cognitive status and its trajectory is
262 currently an unmet medical need in AD research, with circulating gut-derived metabolites presenting
263 a promising area. Metabolic alterations contain rich systemic information on the underlying
264 physiology that connects the periphery to the CNS, likely affecting numerous pathways
265 simultaneously. Thus, the simultaneous detection of numerous perturbed metabolites can provide a
266 powerful detection tool. However, studies investigating composite markers are lacking.

267 16s rRNA sequencing indicated that significant shifts in gut microbiome composition occur during
268 preclinical AD, commencing as early as SCI, suggesting changes may already be apparent when
269 memory complaints first appear, aligning with previous studies^{51,52}. As cognitive decline progresses
270 from SCI to MCI, gut microbiome modulation appears to be less significant. Circulatory metabolites

271 also reflect this pattern, clustering SCI and MCI participants independently from the healthy controls.
272 Individuals with SCI are likely at a higher risk of cognitive decline progression compared to those
273 who are cognitively healthy⁵³, which may lead to greater alterations in biological markers, including
274 the gut microbiome and its metabolites. Procrustes analysis showed significant congruence of the
275 microbiome and metabolome datasets, suggesting the two are interlinked and provides the potential
276 for MDM predictors to be detected early in disease progression. Indeed, gut microbiome composition
277 can account for up to 58% of the variation of circulatory metabolites communicating along the
278 microbiota-gut-brain axis⁵⁴.

279 Targeted metabolomics quantifies metabolites with extremely high sensitivity and accuracy, providing
280 an advantage over the relative responses yielded by untargeted approaches. RF and multiple linear
281 regression models both revealed indoxyl sulfate, choline, 5-hydroxyindole acetic acid, IPA and
282 kynurenic acid as key early indicators of cognitive decline, with RF presenting an AUC predictive
283 performance of 0.74, strongly supporting a significant link between metabolic perturbations
284 associated with the gut microbiome and preclinical AD progression. Previous studies have
285 predominantly concentrated on binary classification approaches, primarily utilising MRI and PET
286 imaging modalities, to investigate AD progression⁵⁵⁻⁵⁷. However, in clinical practice, multiclass
287 classification of blood samples of patients with SCI, MCI and healthy controls could provide a useful
288 approach. Tong and colleagues attained a similar predictive performance (AUC= 0.729) using RF and
289 nonlinear graph fusion of multiple modalities (regional MRI volumes, voxel-based FDG-PET signal
290 intensities, CSF biomarker measures and genetic information) to classify control, MCI and AD
291 participants⁵⁸. AUC increased to 0.84 when predicting healthy ageing and MCI, likely due to the
292 difficulty of diagnosing a patient undergoing SCI. Indeed, Purser and colleagues found no relationship
293 between memory complaints and the progression of cognitive impairment over 10 years in individuals
294 65 years and over⁵⁹. However, others dispute this result⁶⁰. Adjusting our statistical analysis for
295 confounding variables that heavily influence the host, such as age, BMI, kidney function, liver
296 function and background diet, improves analysis robustness and sensitivity. Adjusting for background
297 diet becomes particularly vital when examining MDM as the diet can both modulate gut microbiome
298 composition and provide a variety of bioactive precursor compounds; a factor which is often
299 overlooked in metabolomic analyses⁶¹. Nevertheless, our results highlight the use of profiling select
300 circulatory MDM to identify higher-risk individuals of cognitive decline.

301 Of the five metabolites highlighted by both machine learning and multiple linear regression, all except
302 choline are produced from tryptophan metabolism, indicating notable alterations in tryptophan
303 metabolism may occur in preclinical AD progression. Tryptophan metabolism has previously been
304 well-linked to AD¹⁸. Indeed, we find lower neuroprotective tryptophan-derived metabolites, including
305 IPA and 5-hydroxyindole acetic acid, as cognitive decline progresses from controls to SCI and MCI.
306 IPA is produced in the gut by the microbial conversion of tryptophan via the indole pathway and has

307 previously been investigated as a possible treatment for AD⁶² due to its potent antioxidant effect
308 against A β 1-42 *in vitro*⁶³ and its ability to prevent aggregation and deposition of A β monomers⁶⁴.
309 IPA is anti-inflammatory, reducing the concentration of the proinflammatory TNF- α in activated
310 microglia⁶⁵, lowering the expression of chemokine (CC Motif) ligand 2 (CCL2) and nitric oxide
311 synthase 2 (NOS2) in interferon-beta (IFN- β) activated murine astrocytes⁶⁶ and preventing increases
312 in cytokines in LPS-induced human primary astrocytes⁶⁷, and has previously been identified as a
313 predictor of AD progression⁶⁸. 5-hydroxyindole acetic acid is often used as a surrogate marker for
314 serotonin due to serotonin's rapid degradation. As such, our findings indicate lower peripheral
315 serotonin breakdown as early cognitive decline progresses. Approximately 95% of all serotonin is
316 localised in peripheral compartments where it is involved in the modulation of the enteric nervous
317 system (ENS) development and neurogenesis, gut motility, secretion, inflammation, and epithelial
318 development, suggesting these processes may be disrupted in early cognitive decline⁶⁹. Indeed, MCI
319 and AD patients have often been reported to suffer from gastrointestinal symptoms⁷⁰ and ENS
320 dysregulation in AD has previously been described⁷¹. Decreased concentrations of 5-hydroxyindole
321 acetic acid also suggest a shift in tryptophan metabolism towards the kynurenine pathway, reducing
322 the availability of tryptophan for serotonin synthesis. This is supported by higher serum kynurenine
323 concentrations in SCI and MCI participants in comparison to controls (Supplementary Table S1) and
324 has previously been found in AD participants, linked to poor memory, executive function and global
325 cognition⁷². The kynurenine pathway is activated by an inflammatory stimulus, promoting
326 indoleamine 2,3-dioxygenase, the rate-limiting enzyme that initiates the kynurenine pathway.
327 Increased inflammation is a common feature of AD and as such may play a role in modulating
328 tryptophan catabolites.

329 Both indoxyl sulfate and kynurenic acid concentrations were increased as cognitive decline
330 progressed, even after adjusting for measures of liver and kidney function. As a uremic toxin, indoxyl
331 sulfate can disrupt neuronal efflux transport systems, promote the production of free radicals,
332 inflammation, endothelial cell dysfunction and disturb the circadian rhythm involved in clearing renal
333 and CNS toxins^{73,74}, likely contributing to cognitive decline. Serum levels of indoxyl sulfate, as well
334 as albumin, have previously been identified as predictive of cognitive impairment in participants with
335 end-stage renal disease⁷⁵. End-stage renal disease patients have also been reported to have an
336 increased abundance of the gut bacteria *Holdemania*, in line with our results, suggesting his genera
337 may be underlying the changes between control and SCI⁷⁶. Rodent studies show increased kynurenic
338 acid concentrations can impair cognitive function, including spatial working memory, and broad
339 monitoring deficits^{77,78}. However, data regarding this relationship in human studies is inconsistent
340^{79,80}. Kynurenic acid can play a protective role against the cytotoxic product of the kynurenine
341 pathway, quinolinic acid, by acting as an NMDA antagonist for both glycine and glutamate
342 modulatory sites⁸¹. However, abnormal accumulation has previously been found to induce

343 glutamatergic hypofunction and subsequently disrupt cognitive function⁸². In AD, increased blood
344 concentrations of kynurenic acid have been hypothesised to relate to neuroinflammatory processes
345 and may be produced as a protective response to neuronal damage⁸³.

346 Choline is required for numerous biological functions in the body⁸⁴, notably including hallmark AD-
347 associated processes such as acetylcholine synthesis⁸⁵. As choline readily crosses the blood-brain
348 barrier, peripheral concentrations typically mirror concentrations in the brain⁸⁶, thus lower
349 concentrations in early cognitive decline may indicate decreased central acetylcholine production.
350 Acetylcholine is intricately connected to neural networks regulating memory, and a reduction in this
351 system is closely associated with learning and memory deficits in AD⁸⁷. *Lachnospirillum* and
352 *Lactonifactor* were inversely correlated with choline levels, suggesting changes in these genera may
353 modulate blood concentrations. Indeed, previous research has found *L. saccharolyticum* WM1, a
354 representative strain of *Lachnospirillum*, to be an efficient converter of choline to TMA *in vitro*,
355 transforming at a rate near 100%⁸⁸. This metabolic process *in vivo* also elevated serum TMAO levels
356⁸⁸, which is supported by our results displaying a 1.6-fold higher TMAO in MCI compared to
357 controls. It is likely that increases in *Lachnospirillum* abundance may increase the metabolism of
358 choline to TMAO, decreasing its concentration in circulation.

359 Our study has major strengths including simultaneously targeting some of the top microbial and
360 metabolic metabolites associated with cognitive decline, whilst matching our participants and
361 adjusting our analysis for key factors known to influence the metabolome (age, BMI, sex, liver
362 function, kidney function and background diet), factors rarely accounted for in marker studies.
363 Furthermore, our study highlights key microbiota underlying these metabolic changes, as well as
364 investigating participants from the earliest stage of decline (SCI) and validating our results through
365 machine learning and adjusted statistical approaches. However, some limitations should be stressed.
366 Despite our study adjusting results for key covariates, host metabolome profiles are influenced by a
367 plethora of additional largely environmental and biological factors. Thus, although our findings
368 suggest relationships between the variables, we cannot infer causal relationships from this analysis
369 alone. Moreover, participants' background diet was adjusted for using data collected by food
370 frequency questionnaires, which can be prone to measurement error and may introduce inaccuracies
371 due to recall bias and self-reporting issues. Furthermore, like all studies utilising machine learning
372 models, the larger the dataset, the more robust the predictive performance. With the current dataset
373 including 150 individuals and 32 metabolites, we achieved significant predictive performance.
374 However, our findings will require external validation in larger independent cohorts to improve the
375 model.

376 Pathophysiological progression of AD is apparent up to 20 years prior to clinical symptom onset,
377 making it vital for prevention research to focus on uncovering novel preclinical risk factors. Scalable

378 markers that enable the early detection of at-risk persons could permit the targeting of lifestyle
379 interventions to lessen future risk and uncover novel mechanisms underpinning dementia. Our
380 findings present new insights into the preclinical progression of cognitive decline and dementia. We
381 signify a major role for the gut in connection to the brain through the modulation of key MDM.
382 Furthermore, we lend strength to the hypothesis that individuals with higher risks of cognitive decline
383 can be identified via a targeted metabolomic approach in the preceding stages of AD.

384 **Data availability**

385 The 16S rRNA gene sequence data have been deposited in the NCBI BioProject database
386 (<https://www.ncbi.nlm.nih.gov/bioproject/>) under accession number PRJNA1109848. Other data that
387 support the findings of this study are available from the corresponding authors upon reasonable
388 request.

389

390 **Authors Contributions**

391 D.V. conceptualised the project. A.M.M. provided the human blood and faecal samples. G.L.G.
392 designed the metabolomic analysis, which E.C. and G.L.G. then performed. E.C. conducted the 16S
393 rRNA microbiome sequencing. E.C. and S.S. performed the machine learning analysis. E.C. and M.K.
394 conducted the statistical analysis. E.C. wrote the paper. D.V., S.S., M.K., A.M.M., M.G.P., M.M.,
395 S.M. G.L.G. contributed key discussions in interpreting results and edited the paper. All authors
396 approved the final version of the paper.

397 **Figure Legends**

398 **Figure 1: Microbiome beta diversity is significantly altered in early cognitive decline.** Alpha
399 diversity measured by Chao1 (A) and Shannon H (B) index. (C) Beta diversity as measured by Bray-
400 curtis; p-value generated from PERMANOVA. (D) Pairwise comparisons of the beta diversity
401 analysis.

402 **Figure 2: Metabolic shift occurs in early cognitive decline.** (A) Partial least squares-discriminant
403 analysis (PLS-DA) plot of the metabolomic profiles. (B) Heatmap displaying changes in
404 concentrations of metabolites between the groups, with hierarchical clustering.

405 **Figure 3: Serum metabolome and gut microbiome profiles are linked.** Spearman rank correlation
406 analysis between metabolite and microbiome genera that are significantly modulated in early
407 cognitive decline (A) between control and SCI and (B) between SCI and MCI. (C-H) Abundance
408 counts of microbiome genera correlated with our metabolites of interest (indoxyl sulfate, choline and
409 5-hydroxyindole acetic acid) between control and SCI participants. (I) Abundance count of
410 microbiome genera correlated with metabolite of interest (indole-3-propionic acid) between SCI and
411 MCI, *=p<0.05, **=p<0.01.

412 **Figure 4: Six circulatory metabolites are predictive of preclinical AD.** Receiving Operating
413 Characteristic (ROC) curve illustrating the performance of the Random Forest model for classifying
414 controls, SCI and MCI participants with average area under the curve (AUC) of the multilevel
415 classifier.

416 **5. References**

417

- 418 1. World Health Organization. Global status report on the public health response to dementia.
419 *Security Research Hub Reports* (2021).
- 420 2. Flicker, L. Modifiable Lifestyle Risk Factors for Alzheimer’s Disease. *Journal of Alzheimer’s*
421 *Disease* **20**, 803–811 (2010).
- 422 3. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet
423 Commission. *The Lancet* **396**, 413–446 (2020).
- 424 4. Chakrabarti, A. *et al.* The microbiota-gut-brain axis: pathways to better brain health. Perspectives
425 on what we know, what we need to investigate and how to put knowledge into practice. *Cell Mol*
426 *Life Sci* **79**, 80 (2022).
- 427 5. Connell, E. *et al.* Microbial-derived metabolites as a risk factor of age-related cognitive decline
428 and dementia. *Molecular Neurodegeneration* **17**, 43 (2022).
- 429 6. Li, B. *et al.* Mild cognitive impairment has similar alterations as Alzheimer’s disease in gut
430 microbiota. *Alzheimer’s & Dementia* **15**, 1357–1366 (2019).
- 431 7. Liu, P. *et al.* Altered microbiomes distinguish Alzheimer’s disease from amnesic mild cognitive
432 impairment and health in a Chinese cohort. *Brain, Behavior, and Immunity* **80**, 633–643 (2019).
- 433 8. Nagpal, R. *et al.* Gut mycobiome and its interaction with diet, gut bacteria and alzheimer’s
434 disease markers in subjects with mild cognitive impairment: A pilot study. *EBioMedicine* **59**,
435 102950 (2020).
- 436 9. Brunt, V. E. *et al.* The gut microbiome-derived metabolite trimethylamine N-oxide modulates
437 neuroinflammation and cognitive function with aging. *GeroScience* **43**, 377–394 (2021).
- 438 10. Li, D. *et al.* Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice.
439 *Aging Cell* **17**, e12768 (2018).
- 440 11. Zhuang, Z. *et al.* Causal relationships between gut metabolites and Alzheimer’s disease: a
441 bidirectional Mendelian randomization study. *Neurobiology of Aging* **100**, 119.e15-119.e18
442 (2021).

- 443 12. Hoyles, L. *et al.* Regulation of blood-brain barrier integrity by microbiome-associated
444 methylamines and cognition by trimethylamine N-oxide. *Microbiome* **9**, 235 (2021).
- 445 13. Baloni, P. *et al.* Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and
446 Metabolism in Alzheimer's Disease. *Cell Rep Med* **1**, 100138 (2020).
- 447 14. MahmoudianDehkordi, S. *et al.* Altered Bile Acid Profile Associates with Cognitive Impairment
448 in Alzheimer's Disease – An Emerging Role for Gut Microbiome. *Alzheimers Dement* **15**, 76–92
449 (2019).
- 450 15. Nho, K. *et al.* Altered Bile Acid Profile in Mild Cognitive Impairment and Alzheimer's Disease:
451 Relationship to Neuroimaging and CSF Biomarkers. *Alzheimers Dement* **15**, 232–244 (2019).
- 452 16. Hestad, K., Alexander, J., Rootwelt, H. & Aaseth, J. O. The Role of Tryptophan Dysmetabolism
453 and Quinolinic Acid in Depressive and Neurodegenerative Diseases. *Biomolecules* **12**, 998
454 (2022).
- 455 17. Schwarcz, R., Bruno, J. P., Muchowski, P. J. & Wu, H.-Q. Kynurenines in the mammalian brain:
456 when physiology meets pathology. *Nat Rev Neurosci* **13**, 465–477 (2012).
- 457 18. Weaver, D., Gupta, M., Meek, A., Wang, Y. & Wu, F. Alzheimer's Disease as a Disorder of
458 Tryptophan Metabolism (2745). *Neurology* **94**, (2020).
- 459 19. Whiley, L. *et al.* Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and
460 kynurenine pathway metabolites in both the urine and serum of individuals living with
461 Alzheimer's disease. *Alzheimer's Research & Therapy* **13**, 20 (2021).
- 462 20. Sankowski, B. *et al.* Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl
463 sulfate in patients with Parkinson's disease. *Clinica Chimica Acta* **501**, 165–173 (2020).
- 464 21. Shah, S. N. *et al.* Cerebrovascular damage caused by the gut microbe-derived uraemic toxin p-
465 cresol sulfate is prevented by blockade of the epidermal growth factor receptor.
466 2022.11.12.516113 Preprint at <https://doi.org/10.1101/2022.11.12.516113> (2022).
- 467 22. Smith, M. J., Crowther, R. A. & Goedert, M. The natural osmolyte trimethylamine N-oxide
468 (TMAO) restores the ability of mutant tau to promote microtubule assembly. *FEBS Lett* **484**,
469 265–270 (2000).

- 470 23. Jena, P. K. *et al.* Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-
471 induced systemic inflammation, microglial activation, and reduced neuroplasticity. *FASEB J* **32**,
472 2866–2877 (2018).
- 473 24. Tran, C. D. *et al.* Gut permeability, its interaction with gut microflora and effects on metabolic
474 health are mediated by the lymphatics system, liver and bile acid. *Future Microbiology* **10**, 1339–
475 1353 (2015).
- 476 25. Azevedo, M. L. V. *et al.* p-Cresyl sulfate affects the oxidative burst, phagocytosis process, and
477 antigen presentation of monocyte-derived macrophages. *Toxicol Lett* **263**, 1–5 (2016).
- 478 26. Edamatsu, T., Fujieda, A. & Itoh, Y. Phenyl sulfate, indoxyl sulfate and p-cresyl sulfate decrease
479 glutathione level to render cells vulnerable to oxidative stress in renal tubular cells. *PLoS One* **13**,
480 e0193342 (2018).
- 481 27. Sun, C.-Y., Cheng, M.-L., Pan, H.-C., Lee, J.-H. & Lee, C.-C. Protein-bound uremic toxins
482 impaired mitochondrial dynamics and functions. *Oncotarget* **8**, 77722–77733 (2017).
- 483 28. Tang, W.-H. *et al.* Protein-bounded uremic toxin p-cresylsulfate induces vascular permeability
484 alternations. *Histochem Cell Biol* **149**, 607–617 (2018).
- 485 29. Flanagan, E. *et al.* Chronic Consumption of Cranberries (*Vaccinium macrocarpon*) for 12 Weeks
486 Improves Episodic Memory and Regional Brain Perfusion in Healthy Older Adults: A
487 Randomised, Placebo-Controlled, Parallel-Groups Feasibility Study. *Frontiers in Nutrition* **9**,
488 (2022).
- 489 30. Irvine, M. A. *et al.* The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and
490 progress. *Alzheimers Dement (N Y)* **4**, 591–601 (2018).
- 491 31. Haro, C. *et al.* Intestinal Microbiota Is Influenced by Gender and Body Mass Index. *PLOS ONE*
492 **11**, e0154090 (2016).
- 493 32. Zhang, X. *et al.* Sex- and age-related trajectories of the adult human gut microbiota shared across
494 populations of different ethnicities. *Nat Aging* **1**, 87–100 (2021).
- 495 33. Hollis, J. L. *et al.* Assessing the relative validity of the Scottish Collaborative Group FFQ for
496 measuring dietary intake in adults. *Public Health Nutrition* **20**, 449–455 (2017).

- 497 34. Pontifex, M. G. *et al.* Saffron extract (Safr'Inside™) improves anxiety related behaviour in a
498 mouse model of low-grade inflammation through the modulation of the microbiota and gut
499 derived metabolites. *Food Funct.* **13**, 12219–12233 (2022).
- 500 35. Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naive Bayesian classifier for rapid
501 assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol* **73**,
502 5261–5267 (2007).
- 503 36. Quast, C. *et al.* The SILVA ribosomal RNA gene database project: improved data processing and
504 web-based tools. *Nucleic Acids Res* **41**, D590-596 (2013).
- 505 37. Gowda, S. *et al.* Markers of renal function tests. *N Am J Med Sci* **2**, 170–173 (2010).
- 506 38. Williams, A. L. & Hoofnagle, J. H. Ratio of serum aspartate to alanine aminotransferase in
507 chronic hepatitis. Relationship to cirrhosis. *Gastroenterology* **95**, 734–739 (1988).
- 508 39. Giannini, E. *et al.* Progressive liver functional impairment is associated with an increase in
509 AST/ALT ratio. *Dig Dis Sci* **44**, 1249–1253 (1999).
- 510 40. Tavassol, Z. H. *et al.* Alteration in Gut Microbiota Composition of Older Adults Is Associated
511 with Obesity and Its Indices: A Systematic Review. *The Journal of nutrition, health and aging*
512 **27**, 817–823 (2023).
- 513 41. Leeming, E. R., Johnson, A. J., Spector, T. D. & Le Roy, C. I. Effect of Diet on the Gut
514 Microbiota: Rethinking Intervention Duration. *Nutrients* **11**, 2862 (2019).
- 515 42. Liaw, A. & Wiener, M. Classification and Regression by RandomForest. *Forest* **23**, (2001).
- 516 43. Calle, M. L. & Urrea, V. Letter to the editor: Stability of Random Forest importance measures.
517 *Brief Bioinform* **12**, 86–89 (2011).
- 518 44. Wang, R. AdaBoost for Feature Selection, Classification and Its Relation with SVM, A Review.
519 *Physics Procedia* **25**, 800–807 (2012).
- 520 45. Rish, I. An Empirical Study of the Naïve Bayes Classifier. *IJCAI 2001 Work Empir Methods Artif*
521 *Intell* **3**, (2001).
- 522 46. Hwang, I. K. *et al.* Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the
523 ischemic hippocampus. *J Neurosci Res* **87**, 2126–2137 (2009).

- 524 47. Blusztajn, J. K., Slack, B. E. & Mellott, T. J. Neuroprotective Actions of Dietary Choline.
525 *Nutrients* **9**, 815 (2017).
- 526 48. Klein, C. *et al.* 5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a
527 mouse model for Alzheimer’s disease. *Acta Neuropathologica Communications* **6**, 136 (2018).
- 528 49. Leong, S. C. & Sirich, T. L. Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies.
529 *Toxins* **8**, 358 (2016).
- 530 50. Ostapiuk, A. & Urbanska, E. M. Kynurenic acid in neurodegenerative disorders—unique
531 neuroprotection or double-edged sword? *CNS Neurosci Ther* **28**, 19–35 (2021).
- 532 51. Sheng, C. *et al.* Altered Gut Microbiota in Adults with Subjective Cognitive Decline: The
533 SILCODE Study. *J Alzheimers Dis* **82**, 513–526 (2021).
- 534 52. Chen, G., Zhou, X., Zhu, Y., Shi, W. & Kong, L. Gut microbiome characteristics in subjective
535 cognitive decline, mild cognitive impairment and Alzheimer’s disease: a systematic review and
536 meta-analysis. *Eur J Neurol* **30**, 3568–3580 (2023).
- 537 53. Reisberg, B., Shulman, M. B., Torossian, C., Leng, L. & Zhu, W. Outcome over seven years of
538 healthy adults with and without subjective cognitive impairment. *Alzheimers Dement* **6**,
539 10.1016/j.jalz.2009.10.002 (2010).
- 540 54. Dekkers, K. F. *et al.* An online atlas of human plasma metabolite signatures of gut microbiome
541 composition. *Nat Commun* **13**, 5370 (2022).
- 542 55. Simfukwe, C., Youn, Y. C., Kim, M.-J., Paik, J. & Han, S.-H. CNN for a Regression Machine
543 Learning Algorithm for Predicting Cognitive Impairment Using qEEG. *Neuropsychiatric Disease*
544 *and Treatment* **19**, 851–863 (2023).
- 545 56. Subramanyam Rallabandi, V. P. & Seetharaman, K. Deep learning-based classification of healthy
546 aging controls, mild cognitive impairment and Alzheimer’s disease using fusion of MRI-PET
547 imaging. *Biomedical Signal Processing and Control* **80**, 104312 (2023).
- 548 57. Zubrikhina, M. O. *et al.* Machine learning approaches to mild cognitive impairment detection
549 based on structural MRI data and morphometric features. *Cognitive Systems Research* **78**, 87–95
550 (2023).

- 551 58. Tong, T., Gray, K., Gao, Q., Chen, L. & Rueckert, D. Multi-modal classification of Alzheimer's
552 disease using nonlinear graph fusion. *Pattern Recognition* **63**, 171–181 (2017).
- 553 59. Purser, J. L., Fillenbaum, G. G. & Wallace, R. B. Memory complaint is not necessary for
554 diagnosis of mild cognitive impairment and does not predict 10-year trajectories of functional
555 disability, word recall, or short portable mental status questionnaire limitations. *J Am Geriatr Soc*
556 **54**, 335–338 (2006).
- 557 60. Geerlings, M. I., Jonker, C., Bouter, L. M., Adèr, H. J. & Schmand, B. Association between
558 memory complaints and incident Alzheimer's disease in elderly people with normal baseline
559 cognition. *Am J Psychiatry* **156**, 531–537 (1999).
- 560 61. Playdon, M. C. *et al.* Comparing metabolite profiles of habitual diet in serum and urine. *Am J*
561 *Clin Nutr* **104**, 776–789 (2016).
- 562 62. Bendheim, P. E. *et al.* Development of indole-3-propionic acid (OXIGON) for Alzheimer's
563 disease. *J Mol Neurosci* **19**, 213–217 (2002).
- 564 63. Chyan, Y. J. *et al.* Potent neuroprotective properties against the Alzheimer beta-amyloid by an
565 endogenous melatonin-related indole structure, indole-3-propionic acid. *J Biol Chem* **274**, 21937–
566 21942 (1999).
- 567 64. Cheng, X. & van Breemen, R. B. Mass spectrometry-based screening for inhibitors of beta-
568 amyloid protein aggregation. *Anal Chem* **77**, 7012–7015 (2005).
- 569 65. Kim, C.-S., Jung, S., Hwang, G.-S. & Shin, D.-M. Gut microbiota indole-3-propionic acid
570 mediates neuroprotective effect of probiotic consumption in healthy elderly: A randomized,
571 double-blind, placebo-controlled, multicenter trial and in vitro study. *Clinical Nutrition* **42**, 1025–
572 1033 (2023).
- 573 66. Rothhammer, V. *et al.* Type I interferons and microbial metabolites of tryptophan modulate
574 astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. *Nat*
575 *Med* **22**, 586–597 (2016).
- 576 67. Garcez, M. L., Tan, V. X., Heng, B. & Guillemin, G. J. Sodium Butyrate and Indole-3-propionic
577 Acid Prevent the Increase of Cytokines and Kynurenine Levels in LPS-induced Human Primary
578 Astrocytes. *Int J Tryptophan Res* **13**, 1178646920978404 (2020).

- 579 68. Gao, J. *et al.* The Association of Fried Meat Consumption With the Gut Microbiota and Fecal
580 Metabolites and Its Impact on Glucose Homeostasis, Intestinal Endotoxin Levels, and Systemic
581 Inflammation: A Randomized Controlled-Feeding Trial. *Diabetes Care* **44**, 1970–1979 (2021).
- 582 69. Terry, N. & Margolis, K. G. Serotonergic Mechanisms Regulating the GI Tract: Experimental
583 Evidence and Therapeutic Relevance. *Handb Exp Pharmacol* **239**, 319–342 (2017).
- 584 70. Rao, M. & Gershon, M. D. The bowel and beyond: the enteric nervous system in neurological
585 disorders. *Nat Rev Gastroenterol Hepatol* **13**, 517–528 (2016).
- 586 71. Chalazonitis, A. & Rao, M. Enteric nervous system manifestations of neurodegenerative disease.
587 *Brain Res* **1693**, 207–213 (2018).
- 588 72. Willette, A. A. *et al.* Inflammation, negative affect, and amyloid burden in Alzheimer’s disease:
589 Insights from the kynurenine pathway. *Brain, Behavior, and Immunity* **95**, 216–225 (2021).
- 590 73. Franco, Á. de O., Starosta, R. T. & Roriz-Cruz, M. The specific impact of uremic toxins upon
591 cognitive domains: a review. *J Bras Nefrol* **41**, 103–111 (2019).
- 592 74. Iwata, K. *et al.* Involvement of indoxyl sulfate in renal and central nervous system toxicities
593 during cisplatin-induced acute renal failure. *Pharm Res* **24**, 662–671 (2007).
- 594 75. Hou, Y.-C., Lu, K.-C., Huang, C.-L., Lin, Y.-F. & Chen, R.-M. Serum albumin and indoxyl
595 sulfate were predictive of cognitive impairment via amyloid beta and tauopathy, respectively, in
596 end-stage renal disease patients. *Alzheimer’s & Dementia* **17**, e053921 (2021).
- 597 76. Zheng, L. J. *et al.* Gut dysbiosis-influence on amygdala-based functional activity in patients with
598 end stage renal disease: a preliminary study. *Brain Imaging Behav* **14**, 2731–2744 (2020).
- 599 77. Hahn, B., Reneski, C. H., Pocivavsek, A. & Schwarcz, R. Prenatal kynurenine treatment in rats
600 causes schizophrenia-like broad monitoring deficits in adulthood. *Psychopharmacology (Berl)*
601 **235**, 651–661 (2018).
- 602 78. Pocivavsek, A. *et al.* Fluctuations in endogenous kynurenic acid control hippocampal glutamate
603 and memory. *Neuropsychopharmacology* **36**, 2357–2367 (2011).
- 604 79. Fazio, F. *et al.* Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a
605 Potential Trait Marker for Schizophrenia. *Sci Rep* **5**, 17799 (2015).

- 606 80. Chiappelli, J. *et al.* Stress-induced increase in kynurenic acid as a potential biomarker for patients
607 with schizophrenia and distress intolerance. *JAMA Psychiatry* **71**, 761–768 (2014).
- 608 81. Stone, T. W. & Darlington, L. G. The kynurenine pathway as a therapeutic target in cognitive and
609 neurodegenerative disorders. *Br J Pharmacol* **169**, 1211–1227 (2013).
- 610 82. Fujigaki, H., Yamamoto, Y. & Saito, K. L-Tryptophan-kynurenine pathway enzymes are
611 therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
612 *Neuropharmacology* **112**, 264–274 (2017).
- 613 83. Marrugo-Ramírez, J., Rodríguez-Núñez, M., Marco, M.-P., Mir, M. & Samitier, J. Kynurenic
614 Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer’s Disease.
615 *Biosensors* **11**, 20 (2021).
- 616 84. Zeisel, S. H. & da Costa, K.-A. Choline: An Essential Nutrient for Public Health. *Nutr Rev* **67**,
617 615–623 (2009).
- 618 85. Dave, N. *et al.* Dietary choline intake is necessary to prevent systems-wide organ pathology and
619 reduce Alzheimer’s disease hallmarks. *Aging Cell* **22**, e13775 (2023).
- 620 86. Wurtman, R. J., Cansev, M. & Ulus, I. H. Choline and Its Products Acetylcholine and
621 Phosphatidylcholine. in *Handbook of Neurochemistry and Molecular Neurobiology: Neural*
622 *Lipids* (eds. Lajtha, A., Tettamanti, G. & Goracci, G.) 443–501 (Springer US, Boston, MA,
623 2009). doi:10.1007/978-0-387-30378-9_18.
- 624 87. Poly, C. *et al.* The relation of dietary choline to cognitive performance and white-matter
625 hyperintensity in the Framingham Offspring Cohort1234. *Am J Clin Nutr* **94**, 1584–1591 (2011).
- 626 88. Cai, Y.-Y. *et al.* Integrated metagenomics identifies a crucial role for trimethylamine-producing
627 *Lachnoclostridium* in promoting atherosclerosis. *npj Biofilms Microbiomes* **8**, 1–12 (2022).
- 628

629 **Table 1: Baseline characteristics of the participants.** Mean (SD). P-value calculated using one-way ANOVA.
 630 Significant values at p<0.05 are in bold. SCI: subjective cognitive impairment, MCI: mild cognitive impairment,
 631 TMT: Trail Making Test A or B. Bold p-values represent p<0.05.

632










	Control (N=50)	SCI (N=50)	MCI (N=50)	P-value
Sex, M/ F (%F)	23/27 (54)	23/27 (54)	23/27 (54)	-
Age (years)	65.6 (5.3)	65.5 (6.1)	65.5 (5.8)	0.999
BMI (kg/m ²)	25.1 (3.1)	25.0 (2.9)	25.0 (2.8)	0.993
Education (years)	14.4 (2.6)	14.6 (4.0)	14.6 (3.9)	0.968
% <i>APOE4</i>	18	26	38	0.079
Cognitive tests				
TMT A	30.7 (6.2)	29.3 (8.1)	33.3 (12.1)	0.088
TMAT B	66.4 (20.4)	62.3 (16.5)	74.9 (27.3)	0.015
Digit Span Forwards	11.1 (2.2)	11.2 (1.8)	10.5 (2.6)	0.211
Digit Span Backwards	7.7 (2.0)	7.2 (1.8)	6.5 (2.1)	0.011
Digit Span Total	18.8 (3.8)	18.4 (3.0)	17.0 (4.2)	0.039
Biochemistry				
Creatinine (µmol/L)	73.90 (13.5)	72.5 (12.3)	73.5 (14.1)	0.871
Albumin (g/L)	40.4 (2.4)	30.0 (2.4)	39.4 (2.3)	<0.001
Bilirubin (µmol/L)	12.8 (4.7)	8.9 (5.1)	9.1 (4.4)	<0.001
AST (µL)	21.7 (3.9)	20.6 (5.9)	24.0 (13.1)	0.141
ALT (µL)	16.9 (5.4)	16.7 (9.0)	18.3 (11.3)	0.621
AST/ALT	1.4 (0.3)	1.4 (0.4)	1.4 (0.4)	0.548
Fasting Glucose (mmol/L)	4.8 (0.4)	5.0 (0.5)	5.3 (1.0)	<0.001
Triglyceride (mmol/L)	1.1 (0.5)	1.1 (0.4)	1.2 (0.5)	0.368
Cholesterol (mmol/L)	5.6 (1.1)	5.2 (1.1)	5.2 (1.0)	0.174
HDL Cholesterol (mmol/L)	1.6 (0.4)	1.5 (0.5)	1.5 (0.4)	0.297
LDL Cholesterol (mmol/L)	3.4 (0.1)	3.2 (0.9)	3.1 (0.8)	0.182


633




634
635
636
637

Table 2: Multiple linear regression model (adjusted for age, BMI, liver function (AST/ALT ratio), kidney function (creatinine) and diet) showing metabolites significantly associated with early cognitive decline. Diet was analysed using hierarchical clustering, 'Ward' method, to group individuals with similar dietary patterns. This grouped participants into three dietary groups (low, moderate and high intake of dietary components (Kcal, carbohydrates, fats, protein, water, alcohol, minerals, vitamins). Healthy controls and diet group 2 (moderate intake) were used as reference groups in the model. Bold p-values represent $p < 0.05$.

Explanatory Variable	Metabolite																			
	Indoxyl Sulfate				Choline				5-Hydroxyindole Acetic Acid				Indole Propionic Acid				Kynurenic Acid			
	Beta	P-value	95% CI		Beta	P-value	95% CI		Beta	P-value	95% CI		Beta	P-value	95% CI		Beta	P-value	95% CI	
			Low	High			Low	High			Low	High			Low	High			Low	High
Constant	-2.288	0.482	-8.705	4.128	29.690	0.011	6.938	52.443	0.068	0.020	0.011	0.125	3.094	0.009	0.790	5.397	0.017	0.448	-0.027	0.062
Age	0.057	0.115	-0.014	0.128	0.100	0.434	-0.152	0.351	0.001	0.058	0.000	0.001	-0.007	0.568	-0.033	0.018	<0.001	0.314	-0.001	<0.001
BMI	0.064	0.378	-0.079	0.207	-0.328	0.202	-0.835	0.178	-0.001	0.063	-0.003	0.000	-0.026	0.308	-0.077	0.025	0.001	0.039	<0.001	0.002
Creatinine	0.036	0.028	0.004	0.067	0.105	0.063	-0.006	0.217	0.000	0.493	0.000	0.000	-0.004	0.452	-0.016	0.007	0.001	<0.001	<0.001	0.001
AST/ALT	-1.437	0.011	-2.541	-0.332	0.812	0.681	-3.082	4.706	-0.002	0.710	-0.012	0.008	0.213	0.289	-0.182	0.607	-0.009	0.023	-0.017	-0.001
Diet Group 1	0.354	0.445	-0.559	1.267	1.247	0.445	-1.972	4.466	-0.002	0.690	-0.010	0.006	0.204	0.221	-0.124	0.532	-0.003	0.408	-0.009	0.004
Diet Group 3	0.130	0.829	-1.052	1.311	-0.706	0.740	-4.897	3.486	-0.001	0.826	-0.012	0.009	-0.128	0.568	-0.570	0.314	-0.003	0.450	-0.011	0.005
SCI	1.650	0.001	0.674	2.625	-5.635	0.002	-9.084	-2.187	-0.011	0.012	-0.020	-0.002	-0.181	0.316	-0.536	0.174	0.007	0.037	<0.001	0.014
MCI	1.308	0.008	0.342	2.274	-5.217	0.003	-8.645	-1.789	-0.015	0.001	-0.024	-0.007	-0.558	0.002	-0.910	-0.206	0.001	0.874	-0.006	0.007
Overall change in early cognitive decline	Increased				Decreased				Decreased				Decreased				Increased			





A**B****C****D**

Pair	F-value	R-Squared	P-value	FDR
Control vs SCI	1.77	0.02	0.01 *	0.03 *
SCI vs MCI	1.02	0.01	0.38	0.38
MCI vs Control	1.26	0.01	0.10	0.15

Scores Plot

